Imatinib mesylate tablet and preparation method thereof

A technology of imatinib mesylate and imatinib mesylate, which is applied in the field of imatinib mesylate tablets and its preparation, can solve the problems of discoloration of raw materials, and achieve the effect of convenient operation and simple preparation process
CN103222965AInactive Publication Date: 2013-07-31QINGDAO UNIV
8 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
QINGDAO UNIV
Publication Date
2013-07-31
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an imatinib mesylate tablet and a preparation method thereof. The imatinib mesylate tablet comprises 8-30% of crospovidone and 8 to 40% of silica. The preparation method comprises the following steps of carrying out granulation of imatinib mesylate and a waterless organic solvent, drying the granules, uniformly mixing the granules, crospovidone, silica, a filler and a lubricant, and carrying out tabletting. The preparation method solves the problem of a slow dissolution rate of a preparation obtained by the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to imatinib mesylate tablets and a preparation method thereof. Background technique

[0002] Imatinib mesylate is a selective tyrosine kinase inhibitor developed by Swiss Novartis, which belongs to the anilinoquinazoline compounds. It was approved by FDA in May 2001 for the treatment of chronic myelogenous leukemia. In February 2002, FDA further approved imatinib mesylate for the treatment of gastrointestinal stromal tumors. Imatinib mesylate can inhibit Bcr-Abl tyrosine kinase at the cellular level in vivo and in vitro, and can selectively inhibit Bcr-Abl positive cell line cells, Ph chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia Proliferation and induction of apoptosis in fresh cells from patients. In addition, imatinib mesylate can also inhibit platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More